Skip to main content
Erschienen in: Medical Oncology 1/2015

01.01.2015 | Original Paper

MicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability

Erschienen in: Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

AKT2 is a crucial mediator in the tumorigenesis and thought to be an ideal target for the treatment of malignancies. Increasing evidence has also shown that microRNAs (miRNAs) could regulate or be regulated by mRNAs and they also might serve as therapeutic agencies or targets. MiR-29s (miR-29a, miR-29b and miR-29c) had been approved that they decreased in gastric cancers (GC) by targeting CCND2, MMP2 and p42.3. However, whether miR-29s would target AKT2 have not been investigated in GC. Here, we explored the relationship between miR-29s and AKT2 and found that in GC cell lines (HGC-27 and MGC-803) and GC clinical samples the decreased levels of miR-29s accompanied by increased AKT2 expression. Introduction of miR-29s into GC cells resulted in decreased AKT2 expression and decreased the ability of cancer cells invasion, so did the siRNA-AKT2. Our studies revealed that miR-29s expression is downregulated in GC and they could repress the AKT2 expression and the inactivation of AKT and GSK3beta leading to inhibit the GC cells invasion. Taken together, our findings suggested that AKT2 may be one of the targets of miR29s in gastric cancer. By increasing the expression of miR-29s or decreasing AKT2 expression may be promising in combating with GC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Piazuelo MB, Correa P. Gastric cáncer: overview. Colomb Med (Cali). 2013;44:192–201. Piazuelo MB, Correa P. Gastric cáncer: overview. Colomb Med (Cali). 2013;44:192–201.
2.
Zurück zum Zitat Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26:48–58.PubMedCentralPubMed Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26:48–58.PubMedCentralPubMed
3.
Zurück zum Zitat Acunzo M, Romano G, Wernicke D et al. MicroRNA and cancer—a brief overview. Adv Biol Regul. 2014. pii:S2212-4926:00052-9. Acunzo M, Romano G, Wernicke D et al. MicroRNA and cancer—a brief overview. Adv Biol Regul. 2014. pii:S2212-4926:00052-9.
4.
Zurück zum Zitat Shrestha S, Hsu SD, Huang WY, et al. A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 2014;3(4):878–88.PubMedCrossRef Shrestha S, Hsu SD, Huang WY, et al. A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 2014;3(4):878–88.PubMedCrossRef
6.
Zurück zum Zitat Jiang H, Zhang G, Wu JH, et al. Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014;3:1509–16. Jiang H, Zhang G, Wu JH, et al. Diverse roles of miR-29 in cancer (review). Oncol Rep. 2014;3:1509–16.
7.
Zurück zum Zitat Wu DW, Hsu NY, Wang YC et al. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene. 2014. doi:10.1038/onc.2014.152. Wu DW, Hsu NY, Wang YC et al. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene. 2014. doi:10.​1038/​onc.​2014.​152.
8.
Zurück zum Zitat Yu PN, Yan MD, Lai HC, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014;134:542–51.PubMedCrossRef Yu PN, Yan MD, Lai HC, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014;134:542–51.PubMedCrossRef
9.
Zurück zum Zitat Xu XD, Wu XH, Fan YR, et al. Exosome-derived microRNA-29c induces apoptosis of BIU-87 cells by down regulating BCL-2 and MCL-1. Asian Pac J Cancer Prev. 2014;15:3471–6.PubMedCrossRef Xu XD, Wu XH, Fan YR, et al. Exosome-derived microRNA-29c induces apoptosis of BIU-87 cells by down regulating BCL-2 and MCL-1. Asian Pac J Cancer Prev. 2014;15:3471–6.PubMedCrossRef
10.
Zurück zum Zitat Rostas JW 3rd, Pruitt HC, Metge BJ, et al. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol Cancer. 2014;13:200.PubMedCentralPubMedCrossRef Rostas JW 3rd, Pruitt HC, Metge BJ, et al. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol Cancer. 2014;13:200.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Chen L, Xiao H, Wang ZH, et al. miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. BMB Rep. 2014;47:39–44.PubMedCentralPubMedCrossRef Chen L, Xiao H, Wang ZH, et al. miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. BMB Rep. 2014;47:39–44.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Gong J, Li J, Wang Y, et al. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis. 2014;35:497–506.PubMedCrossRef Gong J, Li J, Wang Y, et al. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis. 2014;35:497–506.PubMedCrossRef
13.
Zurück zum Zitat Matsuo M, Nakada C, Tsukamoto Y, et al. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol Cancer. 2013;12:15.PubMedCentralPubMedCrossRef Matsuo M, Nakada C, Tsukamoto Y, et al. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol Cancer. 2013;12:15.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Cui Y, Su WY, Xing J, et al. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. PLoS One. 2011;6:e25872.PubMedCentralPubMedCrossRef Cui Y, Su WY, Xing J, et al. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. PLoS One. 2011;6:e25872.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Lang N, Liu M, Tang QL, et al. Effects of microRNA-29 family members on proliferation and invasion of gastric cancer cell lines. Chin J Cancer. 2010;29:603–10.PubMedCrossRef Lang N, Liu M, Tang QL, et al. Effects of microRNA-29 family members on proliferation and invasion of gastric cancer cell lines. Chin J Cancer. 2010;29:603–10.PubMedCrossRef
16.
Zurück zum Zitat Romano G. The role of the dysfunctional Akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo). 2013;2013:317186. Romano G. The role of the dysfunctional Akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo). 2013;2013:317186.
17.
Zurück zum Zitat Liu LL, Lu SX, Li M, et al. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget. 2014;5:5113–24.PubMedCentralPubMed Liu LL, Lu SX, Li M, et al. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget. 2014;5:5113–24.PubMedCentralPubMed
18.
Zurück zum Zitat Wang L, Yao J, Zhang X, et al. miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2. Mol Cancer Res. 2014;12(190–202):9. Wang L, Yao J, Zhang X, et al. miRNA-302b suppresses human hepatocellular carcinoma by targeting AKT2. Mol Cancer Res. 2014;12(190–202):9.
19.
Zurück zum Zitat Gong JN, Yu J, Lin HS, et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ. 2014;21:100–12.PubMedCentralPubMedCrossRef Gong JN, Yu J, Lin HS, et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ. 2014;21:100–12.PubMedCentralPubMedCrossRef
Metadaten
Titel
MicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability
Publikationsdatum
01.01.2015
Erschienen in
Medical Oncology / Ausgabe 1/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0342-8

Weitere Artikel der Ausgabe 1/2015

Medical Oncology 1/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.